Terphenyl-Based Bak BH3 α-Helical Proteomimetics as Low-Molecular-Weight Antagonists of Bcl-x <sub>L</sub>

Hang Yin(University of South Florida), Gui-in Lee(University of South Florida), Kristine A. Sedey(Yale University), Olaf Kutzki(Moffitt Cancer Center), Hyung Soon Park(Yale University), Brendan P. Orner(University of South Florida), Justin T. Ernst(University of South Florida), Hong‐Gang Wang(Moffitt Cancer Center), Saı̈d M. Sebti(University of South Florida), Andrew D. Hamilton(Yale University)
Journal of the American Chemical Society
July 1, 2005
Cited by 196Open Access
Full Text

Abstract

We describe a general method for the mimicry of one face of an alpha-helix based on a terphenyl scaffold that spatially projects functionality in a manner similar to that of two turns of an alpha-helix. The synthetic scaffold reduces the flexibility and molecular weight of the mimicked protein secondary structure. We have applied this design to the development of antagonists of the alpha-helix binding protein Bcl-x(L). Using a sequential synthetic strategy, we have prepared a library of terphenyl derivatives to mimic the helical region of the Bak BH3 domain that binds Bcl-x(L). Fluorescence polarization assays were carried out to evaluate the ability of terphenyl derivatives to displace the Bcl-x(L)-bound Bak peptide. Terphenyl 14 exhibited good in vitro affinity with a K(i) value of 0.114 muM. These terphenyl derivatives were more selective at disrupting the Bcl-x(L)/Bak over the HDM2/p53 interaction, which involves binding of the N-terminal alpha-helix of p53 to HDM2. Structural studies using NMR spectroscopy and computer-aided docking simulations suggested that the helix binding area on the surface of Bcl-x(L) is the target for the synthetic ligands. Treatment of human embryonic kidney 293 (HEK293) cells with terphenyl derivatives resulted in the disruption of the binding of Bcl-x(L) to Bax in intact cells.


Related Papers

No related papers found

Powered by citation graph analysis